Home Awareness CHMP Grants Favorable Opinion: Bristol Myers Melanoma
Awareness

CHMP Grants Favorable Opinion: Bristol Myers Melanoma

Bristol Myers Squibb announces that the European Medicines Agency’s CHMP has recommended approval of Opdivo as an adjuvant therapy for patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

This positive opinion is based on safety and efficacy results from the Phase 3 CheckMate -76K trial, in which, with a minimum follow-up of 7.8 months, Opdivo reduced the risk of recurrence or death by 58% compared to placebo.

These results were presented at the 2022 annual meeting of the Society for Melanoma Research (SMR). The European Commission, which has the power to approve medicines in the European Union, will now review the CHMP recommendation.

This article is originally published on boursorama.com

Related Articles

Awareness

Digital Business Ireland Warns of Low Awareness Among Irish Firms on New EU Digital Accessibility Rules

The looming June 28, 2025 deadline for compliance with the European Accessibility...

Awareness

Bilawal-Led Delegation Urges EU Support to Resolve Kashmir Amid Rising India-Pakistan Tensions

A high-level Pakistani delegation headed by former Foreign Minister Bilawal Bhutto Zardari...

UK Heatwave 2025 Record 29.4°C in Santon Downham, Met Office Thunderstorm Warnings
Awareness

UK Heatwave 2025: Record 29.4°C in Santon Downham, Met Office Thunderstorm Warnings

The United Kingdom recorded its warmest day of 2025 so far as...

Awareness

Man Walks Over 1,200 Miles to Raise Awareness for Motor Neurone Disease (MND)

Aidan Courts, a determined man from Redditch, has embarked on an extraordinary...